Evidence map›Paper›PMID 28163231›Full record

ArticleInternational journal of pharmaceutics2017

Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.

Sharon S Y Leung, Thaigarajan Parumasivam, Fiona G Gao, Elizabeth A Carter, Nicholas B Carrigy, Reinhard Vehring, Warren H Finlay, Sandra Morales, Warwick J Britton, Elizabeth Kutter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. EudragitPharmaceutics · 2023
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Development of a Phage Cocktail to TargetPharmaceuticals (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sharon S Y LeungFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Thaigarajan ParumasivamFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Fiona G GaoFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Elizabeth A CarterVibrational Spectroscopy Core Facility, The School of Chemistry, University of Sydney, Sydney, NSW 2006, Australia.
Nicholas B CarrigyDepartment of Mechanical Engineering, University of Alberta, Alberta, T6G 2G8, Canada.
Reinhard VehringDepartment of Mechanical Engineering, University of Alberta, Alberta, T6G 2G8, Canada.
Warren H FinlayDepartment of Mechanical Engineering, University of Alberta, Alberta, T6G 2G8, Canada.
Sandra MoralesAmpliPhi Biosciences AU, 7/27 Dale Street, Brookvale, Sydney, NSW, 2100, Australia.
Warwick J BrittonTuberculosis Research Program, Centenary Institute and Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
Elizabeth KutterThe Evergreen State College, Olympia, WA, 98502, USA.
Hak-Kim ChanFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia. Electronic address: kim.chan@sydney.edu.au.

Funding

Harnessing bacteriophages as natural predators to combat the superbugs: a pulmonary drug delivery approachR21AI121627 · NIAID · UNIVERSITY OF SYDNEY · PI CHAN, KIM · 2016 to 2017
$287k
NIAID NIH HHS R21 AI121627
6 · The paper itself

Abstract

This study aimed to develop inhalable powders containing phages active against antibiotic-resistant Pseudomonas aeruginosa for pulmonary delivery. A Pseudomonas phage, PEV2, was spray dried into powder matrices comprising of trehalose (0-80%), mannitol (0-80%) and l-leucine (20%). The resulting powders were stored at various relative humidity (RH) conditions (0, 22 and 60% RH) at 4°C. The phage stability and in vitro aerosol performance of the phage powders were examined at the time of production and after 1, 3 and 12 months storage. After spray drying, a total of 1.3 log titer reduction in phage was observed in the formulations containing 40%, 60% and 80% trehalose, whereas 2.4 and 5.1 log reductions were noted in the formulations containing 20% and no trehalose, respectively. No further reduction in titer occurred for powders stored at 0 and 22% RH even after 12 months, except the formulation containing no trehalose. The 60% RH storage condition had a destructive effect such that no viable phages were detected after 3 and 12 months. When aerosolised, the total lung doses for formulations containing 40%, 60% and 80% trehalose were similar (in the order of 10

Indexed as

DesiccationAdministration, InhalationBacteriophagesCrystallizationDrug StabilityDrug StorageHumidityParticle SizePowdersPseudomonas aeruginosaX-Ray DiffractionPowdersMDRMulti-drug resistancePEV2PhagePulmonary infectionSpray drying

Identifiers

PMID28163231
PMCPMC5389863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.